Invex Therapeutics Ltd (ASX:IXC)

Australia flag Australia · Delayed Price · Currency is AUD
0.130
-0.010 (-7.14%)
Apr 29, 2026, 12:28 PM AEST
73.33%
Market Cap 9.77M
Revenue (ttm) 229.08K
Net Income (ttm) -835.92K
Shares Out 75.15M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 80,687
Average Volume 35,976
Open 0.140
Previous Close 0.140
Day's Range 0.130 - 0.140
52-Week Range 0.074 - 0.180
Beta 0.37
RSI 64.78
Earnings Date May 13, 2026

About Invex Therapeutics

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, A... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol IXC
Full Company Profile

Financial Performance

In fiscal year 2025, Invex Therapeutics's revenue was 229,084, a decrease of -81.10% compared to the previous year's 1.21 million. Losses were -476,868, -70.95% less than in 2024.

Financial Statements

News

There is no news available yet.